Aimmune Therapeutics Inc (NASDAQ:AIMT) CFO Eric Bjerkholt acquired 3,125 shares of the business’s stock in a transaction on Monday, February 26th. The shares were purchased at an average cost of $32.00 per share, for a total transaction of $100,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Aimmune Therapeutics Inc (AIMT) opened at $31.67 on Wednesday. Aimmune Therapeutics Inc has a 12-month low of $15.97 and a 12-month high of $42.00.
Institutional investors and hedge funds have recently modified their holdings of the company. First Republic Investment Management Inc. bought a new stake in shares of Aimmune Therapeutics in the 4th quarter worth approximately $202,000. Virtu Financial LLC bought a new stake in shares of Aimmune Therapeutics in the 4th quarter worth approximately $239,000. Daiwa SB Investments Ltd. boosted its position in shares of Aimmune Therapeutics by 44.5% in the 4th quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 2,245 shares in the last quarter. Teacher Retirement System of Texas bought a new stake in shares of Aimmune Therapeutics in the 4th quarter worth approximately $282,000. Finally, SG Americas Securities LLC boosted its position in shares of Aimmune Therapeutics by 54.7% in the 3rd quarter. SG Americas Securities LLC now owns 8,430 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 2,979 shares in the last quarter. 66.59% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Eric Bjerkholt Acquires 3,125 Shares of Aimmune Therapeutics Inc (AIMT) Stock” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3227404/eric-bjerkholt-acquires-3125-shares-of-aimmune-therapeutics-inc-aimt-stock.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.